Well this might end up being a good move here as there’s much to gain. At least invest in something that has the potential to improve and save lives rather than to over deluge us with more social software. Don’t misunderstand here, I use and like social medias and it works well for me with...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
01-06-2009
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, personalized medicine, healthcare, Biotech, Cancer, R and D, Start Ups, Venture Capital, Web 2.0
It is here but evolving slower than what all of us might like to see, and in many areas it is still so much of a “Science” but as developments occur through biotech we are seeing some amazing results. There’s also the bridging of the gap with bringing genomics to the point of care, as physicians...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-26-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Pharma, Biotech, Cancer, tumors, Genentech, Herceptin, cancer vaccine
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-05-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
Right now according to the Wall Street Journal, patients who have enjoyed an open relationship are worried that this could all change under management from Roche. Is bigger always better? Recently in the news Genentech is not happy with the offer and may hold out for more. Anyone that...
Mark up one more purchase for Roche this week. Pharmaceutical companies are looking for for biotech purchases and Roche is not wasting one moment this week. Arius fits right in with current ongoing cancer research. Who will be on the list tomorrow? BD Roche announced this...
One Biotech looking for money with their focus on cancer treating drugs in various stages of clinical trials. BD Seattle-based Cell Therapeutics is sending out an SOS signal to investors. "We have an immediate need to raise additional capital in the next thirty days in order to meet...
Good insight and commentary here from the "inside" track...are members of Congress helping or stalling the progression of the FDA... will the Biotechs be able to develop and withstand some of the stringencies and additional methodologies to bring new products to market to save lives? Nice to...